An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...